Drug Supply Chain Security Act (DSCSA) Resources for Dispensers.

A resource page developed collaboratively among supply chain trading partners to house educational information dispensers may find useful to assist in implementation of the DSCSA.



What is DSCSA?

The DSCSA, enacted in 2013, preempts a 50-state patchwork of pedigree requirements to create one federal traceability framework for prescription medicines. The DSCSA sets out a 10-year timeline to build an electronic, interoperable system for the exchange of transaction documentation [transaction information (TI), transaction history (TH) and transaction statements (TS)] to enable the tracing of prescription medicines throughout the pharmaceutical supply chain, with the final milestone quickly approaching in November, 2023.

DSCSA defines a dispenser as:

  • A retail pharmacy;
  • A hospital pharmacy;
  • A group of chain pharmacies under common ownership and control that do not act as a wholesale distributor; or
  • Any other person authorized by law to dispense or administer prescription drugs and the affiliated warehouses or distribution centers of such entities under common ownership and control that do not act as a wholesale distributor

Overview of DSCSA Milestones


Lot-level traceability

Manufacturers and wholesale distributors must provide lot TI, TH and TS.


Product identifiers by manufacturers

Manufacturers must affix product identifiers to each package and homogenous case.


Product identifiers by repackagers

Repackagers must affix product identifiers to each package and homogenous case.


Verification by distributors

Wholesale distributors must only accept serialized product. They must also verify product identifiers with the manufacturer before redistributing returns. However, FDA has announced, by way of a “compliance policy” that it will not enforce this saleable returns verification requirement until November 27, 2023. The compliance policy is limited to the requirements that wholesale distributors verify saleable returned products prior to further distribution and have verification systems in place to comply with the requirements of section 582(c)(4)(D) of the FD&C Act; it does not extend to the other requirements in section 582 of the FD&C Act.


Verification by dispensers

FDA has announced in this compliance policy that it will not enforce until November 27, 2023, two dispenser verification requirements that went into effect on November 27, 2020.  Without this enforcement discretion, beginning November 27, 2020, dispensers would have been required to verify the product identifier, including the standardized numerical identifier, of at least 3 packages or 10 percent of such suspect product, whichever is greater, or all packages, if there are fewer than 3. Dispensers would also have had to verify product in this manner (3 packages/10 percent) in response to a notification of illegitimate product from FDA or a trading partner. Dispensers now do not have to verify suspect and illegitimate product in this manner until November 27, 2023. Other requirements, however, are still in effect. Dispensers must still only transact product encoded with a product identifier (unless the product is grandfathered or subject to an applicable waiver, exemption or exception) and must comply with other suspect and illegitimate verification requirements, including quarantining such products, conducting investigations, and dispositioning illegitimate products.


Unit-level traceability

Manufacturers, distributors and dispensers must provide and receive TI (including product identifier) and TS in a secure, electronic and interoperable manner.